Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.51 |
| ▸ | ERN1 | O75460 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315514 | 0.84 | PDE10A (0.56) | SMN1; SMN2ALDH1A1GAAKDM4ENPC1 | |
| SCHEMBL458722 | 0.79 | ERN1 (0.45) | CYP2A6ERN1SMN1; SMN2CYP11B1CYP19A1 | |
| SCHEMBL457853 | 0.78 | CYP2A6 (0.47) | CYP2A6ERN1SMN1; SMN2TTKKDM4E | |
| SCHEMBL29796545 | 0.77 | CYP2A6 (0.55) | CYP2A6SMN1; SMN2RAD51LCKCYP11B1 | |
| SCHEMBL17942777 | 0.77 | CYP2A6 (0.55) | CYP2A6SMN1; SMN2RAD51LCKCYP11B1 | |
| SCHEMBL3722967 | 0.77 | PDE10A (0.70) | CYP2A6SMN1; SMN2RAD51LCKCYP11B1 | |
| SCHEMBL2598835 | 0.77 | CYP2A6 (0.51) | CYP2A6RAD51LCKCYP11B1CYP19A1 | |
| SCHEMBL29636229 | 0.77 | PDE10A (0.47) | SMN1; SMN2ALDH1A1GAAKDM4ENPC1 | |
| SCHEMBL28736545 | 0.77 | PDE10A (0.47) | SMN1; SMN2ALDH1A1GAAKDM4ENPC1 | |
| SCHEMBL16712516 | 0.76 | ERN1 (0.42) | CYP2A6ERN1SMN1; SMN2CYP11B1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153996-B | As quinoline and the quinoxaline derivatives of kinase inhibitor | UCB PHARMA S.A. (BE) | 2016-01-27 | — | — | CN | disclosed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| CN-103153996-A | Quinoline and quinoxaline derivatives as kinase inhibitors | UCB PHARMA SA | 2013-06-12 | — | — | CN | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | CYP2A6 2551/4885ERN1 713/4885SMN1; SMN2 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.